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Abstract
Triple-negative breast cancer (TNBC) represents a heterogenous subtype of breast cancer with generally poor prognosis. The
prediction of its prognosis remains essential to clinicians in their therapeutical decision-making process. The aim of our study was
to compare the validity of three multivariable analysis derived prognostic systems, the Nottingham Prognostic Index (NPI),
PREDICT and PrognosTILs (a prognosticator including tumor infiltrating lymphocytes, TILs) in a series of TNBCs. Patients
operated on with TNBC at the Department of Surgery, Bács-Kiskun County Teaching Hospital, Kecskemét between 2005 and
2016 were included. Clinical and pathological parameters and follow-up data were collected from medical charts. TILs were
assessed retrospectively, following international recommendations. Estimated survivals of PrognosTILs, PREDICT and NPI
were recorded and compared with real outcomes. Altogether 136 patients were included in this retrospective study. In univariate
Cox analysis, type of surgery, pT, pN, stage, NPI and type of adjuvant therapy were the significant prognostic variables. The
multivariate Cox-regression strengthened that NPI is an independent predictor of overall and disease-free survivals in TNBCs.
The NPI, PREDICT and PrognosTILs could be compared directly only in a ROC curve analysis: the sensitivities and specificities
of these predicting systems are rather similar with area under the curve values falling between 0.7 and 0.8, and NPI having the
highest values. Our findings reflect the diverse prognosis of TNBC and highlight the difficulties of predicting its outcome. None
of the three multivariable prognosticators is inferior to the others, the NPI can reliably be used for TNBCs.
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Introduction
Triple-negative breast cancer (TNBC) represents a heteroge-
neous subtype of breast cancer (BC) defined by the lack of
immunohistochemical expression of estrogen receptor (ER),
progesterone receptor (PR) and human epidermal growth fac-
tor receptor-2 (HER2), and by variable though distinct molec-
ular profiles [1, 2]. Epidemiological data on TNBC revealed
its higher prevalence among women of African ancestry,
young BC patients and patients with Breast Cancer Gene-1
(BRCA-1) mutations [3]. The treatment of TNBC remains a
challenge for clinicians due to its poor overall prognosis.
Distant hematogenous metastasis formation and local recur-
rence are frequent and the treatment efficiency of TNBC is
lower than in other types of BC [1, 4, 5]. By taking molecular
profiles and BRCA deficiency into account, more personal-
ized treatment methods are currently available [6]. Besides
chemo- and radiotherapy, the role of immuno- and targeted
therapy is increasing, both being currently under investigation
with promising results [7–9].
Prediction of prognosis remains essential to clinicians in
their decision-making process, helps stratifying patients by
risk and better allows preparing individual treatment plans
[10]. Various prognostic factors have already been presented
in TNBC. Ovcaricek and coauthors described nodal status and
age as independent prognostic factors for disease-free survival
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(DFS), whereas for overall survival (OS), only nodal status
proved to be an independent factor [11]. Urru et al. have dem-
onstrated that tumor stage at diagnosis and positive lymph
node ratio are relevant predictors of survival and tumor recur-
rence, with the addition of Ki-67 status for recurrence predic-
tion [12]. Asaga and coworkers have used a different ap-
proach, and analyzed clinical response to preoperative system-
ic chemotherapy [13].
The Nottingham Prognostic Index (NPI) was described by
Haybittle and coauthors in 1982 and it was originally designed
for primary operable BC. It takes tumor size, nodal stage and
tumor histological grade into consideration [14]. On the basis
of its equation and the values of the NPI, patients’ could be
divided into three prognostic categories according to the orig-
inal article: Category I (good prognosis); Category II (moder-
ate prognosis) and Category III (poor prognosis) [14, 15].
Later the prognostic groups were subdivided to form the very
good, the good, the moderate I, the moderate II, the poor and
the very poor prognostic groups [16]. Different cut-off values
and diverse definitions of NPI-based groups (ranging from
three to ten classes) have been used by some research groups
[10]. The NPI has been proven to be a valid prognostic tool in
BC treatment [17].
A more complex prognostic model, PREDICT was pub-
lished by Wishart and coauthors in 2010. The algorithm was
developed from 5694 patients’ data from the Eastern Cancer
Registration and Information Centre. The selected patients
were operated on for invasive breast cancer. Based on the
factors that were found to hold independent prognostic value,
an algorithm was established that includes the presence of
ductal carcinoma in situ (DCIS) or lobular carcinoma in situ
(LCIS), age at diagnosis, menopausal state, ER, PR, HER2
and Ki-67 status, invasive tumor size, tumor grade, method of
tumor detection and number of positive lymph nodes [18].
PREDICT is also endorsed by the American Joint
Committee of Cancer [19]. The on line calculator estimates
OS for 5, 10 and 15 years. Although the tool generally re-
ceived good ratings for validity, Maishman and coauthors’
results showed that PREDICT was a great tool only in long-
term survival estimates, and overestimated short-time sur-
vivals, especially in ER-positive tumors [17, 20, 21].
Tumor infiltrating lymphocytes (TILs) reflect prognosis in
TNBC, since their higher proportion correlates with better
outcome in this subset of breast tumors, and indicates the
prominent role the immune system plays in TNBC. While
TNBCs lack targeted therapy, the interest for immune modu-
lators has increased [22, 23]. Loi and coworkers conducted a
pooled analysis of 2148 patients and identified the following
factors that independently influence the prognosis of primary
TNBCs: percentage of stromal TILs, age, tumor size, number
of positive lymph nodes, histological grade and treatment.
Invasive disease-free survival (i-DFS), distant disease-free
survival (d-DFS) andOS results were examined in 3 and 5 year
intervals [24]. Based on the results, an equation was devel-
oped for survival estimates. For easier utilization, an online
tool named PrognosTILs was developed for early stage
TNBCs [25]. With this application, the 5-year and 10-year
OS and DFS estimates can be calculated.
The aim of our study was to compare the validity of NPI,
PREDICT and PrognosTILs in a series of TNBC cases.
Materials and Methods
Patients operated on for histologically verified triple negative,
invasive breast carcinoma at the Department of Surgery, Bács-
Kiskun County Teaching Hospital, Kecskemét between 2005
and 2016 were included in our consecutive and retrospective
study. Follow up data (OS and DFS) were collected from
medical charts. For these outcomes, patients were followed
from the date of surgical treatment until the time of recurrence
or tumor-related death; those alive without recurrence and
those dying from other causes were censored at the time of
the last follow-up and death, respectively.
The following clinical and pathological variables were ob-
tained for analysis: age, gender, localization, type of surgical
and adjuvant treatments, histological type and grade of cancer,
vascular invasion, tumor size, pT and pN categories, and
stage. The NPI was calculated with the following equation:
NPI = tumor size (cm) × 0.2 + nodal score (1 for pN0, 2 for
pN1, 3 for pN2 or pN3) + number value from the histological
grade [14]. The Nottingham Prognostic Groups were classi-
fied as excellent (EPG): ≤2.4; good (GPG): 2.41–3.4;
moderate-1 (MPG1): 3.41–4.4; moderate-2 (MPG2): 4.41–
5.4; poor (PGP): 5.41–6.4 and very poor (VPPG): ≥6.41 [16].
The predicted OS and DFS estimates of PrognosTILs were
obtained from an online calculator [23, 25]. The estimations
were based on the following parameters: age, number of pos-
itive lymph nodes, tumor size, histological grade, type of che-
motherapy and proportion of stromal TILs. For the determi-
nation of the latter, the International TILs Working Group
(later acting as International Immunooncology Biomarker
Working Group - IIOBWG) recommendations and rules were
used [25, 26]. To help in the estimation of stromal TILs, the
online calibration system described by the IIOBWG and
found at was also used [27, 28]. After getting accustomedwith
the scoring system with a hundred cases evaluated in a study
by the European Working Group for Breast Screening
Pathology, the calibration (etalon) pictures for different rates
of stromal TILs were screensaved and printed, and these
printed pictures were compared with the microscopic images
displayed on a monitor for at least three areas. The mean of
these estimates was rounded to the closest 10% value also
allowing for 5% and 1%, with the help of the calibration
picture published in the first article of the IIOBWG for the
latter value [29].
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The anticipated OS evaluations of PREDICT were deter-
mined with the online calculator, that required the following
data: age, menopausal state, ER status, HER-2 status, Ki67
status, size of invasive tumor, grade of tumor, type of detec-
tion, number of positive lymph nodes and presence of
micrometastasis in the lymph nodes [18, 19].
The Wilcoxon rank sum test was applied to analyze the
correlation between recurrence or tumor-specific death and
DFS or OS prediction rate of PrognosTILs and OS prediction
rate of PREDICT. The OS and DFS data could not be correlat-
ed directly with the survival predictions of PrognosTILs and
PREDICT, therefore the patients were classified in the follow-
ing four categories: patients alive, patients who died of disease
(DOD), patients alive with and without recurrence. The calcu-
lated OS and DFS survival predictions of PrognosTILs, the OS
survival estimates of PREDICT and NPI scores were correlated
with the 4 categories by receiver operating characteristic (ROC)
curve analysis aiming to compare them and to find cut-off
points. Patients DOD and patients alive categories were utilized
in ROC curve analysis focusing on 5-year-OS prediction of
PrognosTILs, PREDICT and NPI scores, while patients with
recurrence and patients without recurrence categories were used
in a ROC curve of 5-year-DFS estimates of PREDICT and NPI
scores. The cut-off points identified by ROC curve analysis
could show which OS and DFS rates of PrognosTILs, OS es-
timates of PREDICT and NPI scores are related to more fre-
quent recurrence and tumor-specific death, respectively.
NPI was analyzed with the Kaplan-Meier method and the
subgroups were compared with the log rank test. Cox-
regression was utilized as univariate analysis. The parameters
found significant in the univariate models were entered in a
multivariable Cox proportional hazard model to identify factors
of independent prognostic significance. PrognosTILs and
PREDICT survival estimates could not be included in the mul-
tivariate analysis due to statistical reasons. Statistical models
were fitted using SPSS Statistics V.23.0 software (IBM, SSPS
22.0, Armonk, NYUSA). All statistical tests were two-sided and
p < 0.05 values were considered statistically significant.
This retrospective study was approved by the institutional
ethical committee of the Albert Szent-Györgyi Clinical Centre
of the University of Szeged and the ethical committee of Bács-
Kiskun County Teaching Hospital also gave a consent for the
study.
Table 1 Clinical and pathological characteristics of patients evaluated
and the results of univariate Cox-regression [pT, pN categories defined by
AJCC [27: Amin-AJCC], CMF: cyclophosphamide, methotrexate and 5-
fluorouracil; second generation systemic treatment refers to anthracycline
based regimens without taxanes; third generation refers to taxane contain-
ing regimens]
pOS pDFS
Age (years) n % p = 0.102 p = 0.207
30–39 12 9.5
40–49 15 11.9
50–59 37 29.3
60–69 35 27.8
70–79 21 16.7
80–91 6 4.8
Laterality p = 0.645 p = 0.958
Right 58 46.0
Left 68 54.0
Type of surgery p = 0.354 p = 0.017
Mastectomy 24 19.0
Breast conserving surgery 102 81.0
Histology diagnosis p = 0.626 p = 0.566
Carcinoma of no special type (NST) 112 88.8
Medullary carcinoma 7 5.6
Other 7 5.6
Grade p = 0.967 p = 0.88
2 5 4.0
3 121 96.0
pT p = 0.222 p = 0.009
pT1 67 53.1
pT2 55 43.7
pT3 1 0.8
pT4 3 2.4
pN p = 0.006 p < 0.001
pN0 75 59.6
pN1mi 8 6.3
pN1 31 24.6
pN2 9 7.1
pN3 2 1.6
pNx 1 0.8
Vascular invasion p = 0.573 p = 0.400
Absent 100 79.4
Present 26 20.6
Stage p = 0.05 p < 0.001
I 47 37.3
II 51 40.5
III 27 21.4
no data 1 0.8
Adjuvant therapy p = 0.151 p = 0.003
Chemotherapy 10 7.9
Radiotherapy 15 11.9
Both 85 67.5
Neither 16 12.7
Table 1 (continued)
pOS pDFS
Generation of chemotherapy p = 0.092 p = 0.303
Second generation 16 12.7
Third generation 73 57.9
Other (CMF) 6 4.8
No data 31 24.6
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Results
Altogether, 136 patients who underwent surgical resection were
included in our study. Ten patients (7.4%) were censored due to
non-tumor related death. Tumor-specific death was found in 23
cases (16.9%), while 103 patients (75.7%) were alive at the last
follow up, including 20 patients with recurrence (14.7%). The
mean and median OS and DFS were 66.8 months and
57.5 months, 59.9 months and 41 months, respectively (range
for OS: 7–170 months; range for DFS: 2–170 months).
Recurrence was observed in 43 cases, including 11 cases
(25.6%) with local or regional recurrence, 23 cases (53.5%) with
distant metastasis and two cases with both local and distant types
of recurrence. The median time to recurrence was 41 months
(range: 2–170 months) Novel malignancies were found in 3
cases (7.0%; ovary [n = 1] and lung cancer [n = 2]). The median
follow up was 56 months (range: 7–170 months).
The basic clinical and pathological characteristics are
displayed in Table 1 [30]. The mean and median age of the
patients were 59.6 and 59 years, respectively (range: 32–91).
In univariate Cox-regression, the type of surgery, the pT and
pN categories, the stage of the disease and the type of adjuvant
therapy were found to be significant variables.
The predictions from PrognosTILs and PREDICT and the
NPI scores were established in 93, 126 and 125 cases, respec-
tively. Concerning the 5-year-OS and -DFS predictions of
PrognosTILs, the mean, the median and the range of estimates
are presented in Table 2. The comparison of predicted survival
estimates and outcomes revealed that the predicted OS estimates
of the patient DOD were significantly lower than those of pa-
tients who were alive (p = 0.015); similarly, the predicted DFS
estimates of patients with recurrence were significantly lower,
than those of patients without recurrence (p < 0.001). Table 3
highlights the mean, the median and the range of the 5-year-
OS estimates of PREDICT. The statistical analysis strengthened,
that the predicted OS estimates of patient DODwere significant-
ly lower, than those of patients who were alive (p = 0.020).
The NPI-based GPG included only 3 cases, therefore this
group was excluded from further evaluation. Figure 1 demon-
strates the results ofKaplan-Meier analysis of theNPI subgroups.
Significant differences were detected between OS and DFS esti-
mations of different prognostic groups, namely the OS estimates
of MPG1 vs. PPG (p = 0.017), MPG1 vs. VPPG (p = 0.049),
MPG2 vs. PPG (p = 0.026); and the DFS estimates of PPG vs.
MPG1 (p= 0.002), PPG vs. MPG2 (p = 0.035), PPG vs. VPPG
(p= 0.013), VPPG vs. MPG1 (p < 0.001) and VPPG vs. MPG2.
(p= 0.001). In the univariate Cox-regression, NPI was found to
be a significant prognostic variable (pOS = 0.022; HR:1.71,
95%CI:1.08–2.72; pDFS<0.001; HR:2.02, 95%CI:1.43–2.86).
Figure 2 displays the results of ROC curve analysis focus-
ing on 5-year-OS estimates of PrognosTILs, PREDICT and
NPI scores. The area under the curve (AUC) of PrognosTILs,
PREDICT andNPI were 0.759, 0.762 and 0.792, respectively.
Figure 3 demonstrates the ROC curve analysis of 5-year-DFS
estimates of PrognosTILs and NPI scores. The AUC values of
PrognosTILs and NPI were 0.713 and 0.781, respectively.
The findings of ROC curve analyses drew attention to the
similarities of these predictive systems concerning sensitivity
Table 2 The 5-year overall survival (OS) and disease-free survival (DFS) predictions of PrognosTILs according to outcome. Significant differences
were detected between OS predictions of patients who died of disease and patients alive, and DFS predictions of patients with and without recurrence
PrognosTILs predictions average median range Wilcoxon-
test
n % OS DFS OS DFS OS DFS pOS = 0.015
Patients deceased due to tumor 14 15.0 80.1 80.6 80 76 74–92% 69–92%
Patients alive 79 85.0 85 82 85 83 49–95% 44–95%
Patients with recurrence 27 29.0 80.3 77.3 80 77 49–93% 44–93% pDFS < 0.001
Patients alive with recurrence 13 14.0 80.6 77.7 83 80 49–93% 44–93%
Patients alive without recurrence 66 71.0 85.8 84 86 83 71–95% 67–95%
All (where PrognosTILs was evaluated) 93 100.0 84.2 81.7 84 82 49–95% 44–95%
Table 3 The basic characteristics of 5-year overall survival (OS) predictions of PREDICT according to outcome. The survival estimates of patients
dying of tumor progression were lower than those of patients who were alive at last follow up
PREDICT estimates Wilcoxon-test
n % mean median range pOS = 0.020
Patients deceased due to tumor 23 18.3 62.9 65.5 9.2–85.1%
Patients alive 103 81.7 71.8 78.1 7.1–86.5%
All (where PREDICT was evaluated) 126 100 70.1 75.3 7.1–86.5%
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and specificity and to the fact that they are not ideal for defin-
ing cut-off values.
The multivariate Cox proportional hazard model revealed
that among the variables found significant in univariate models
(type of surgery, pT, pN, stage, adjuvant therapy and NPI), only
NPI was an independent prognostic marker for triple negative
breast cancer (pOS = 0.006; HR:1.66, 95%CI:1.16–2.37;
pDFS<0.001; HR:1.92, 95%CI:1.46–2.53).
Discussion
TNBCs are generally considered as the worst IHC based mo-
lecular subtype of breast cancer, owing to their poor prognosis
and the limited therapeutic success associated with them.
Despite the overall bad prognosis of TNBC, there are some
tumors that by definition fall into this category, but belong to a
better prognostic group. These include rare tumors like tall
cell carcinoma with reversed polarity, secretory carcinoma,
non-high grade, i.e. classical adenoid cystic carcinoma
[31–33]. Even without these low grade special type carcino-
mas, the prognosis of TNBC is heterogeneous and depends on
a number of prognostic factors.
The presence of distant metastasis, nodal status, tumor size
and histological grade are established prognostic factors of
breast carcinomas, and have their role in predicting the out-
come of TNBCs as well. More recently the proportion of
stromal TILs has also been recognized as an independent
Fig. 1 Kaplan-Meier analysis of NPI. According to the log rank test
significant differences were observed between the overall survival (OS)
estimates of MPG1 vs. PPG (p = 0.017), MPG1 vs. VPPG (p = 0.049)
andMPG2 vs. PPG (p = 0.026); and the disease-free survival (DFS) esti-
mates of PPG vs. MPG1 (p = 0.002), PPG vs. MPG2 (p = 0.035), PPG vs.
VPPG (p = 0.013), VPPG vs. MPG1 (p < 0.001) and VPPG vs. MPG2
(p = 0.001) [MPG1: Moderate Prognostic Group 1, MPG2: Moderate
Prognostic Group 2, PPG: Poor Prognostic Group, Very Poor
Prognostic Group]
Fig. 2 ROC curve analysis of 5-year overall survival predictions of TIL,
PREDICT and NPI scores (area under the curve values for TIL,
PREDICT and NPI were 0.759, 0.762 and 0.792, respectively)
Fig. 3 ROC curve analysis of 5-year disease-free survival predictions of
PrognosTILs and NPI scores (area under the curve values for TIL and
NPI were 0.713 and 0.781, respectively)
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prognosticator of TNBCs [24], and the prognostic value of
TILs was also found in a more recent meta-analysis [34].
When prognostic factors show divergent features, i.e. clini-
cians are faced with a combination of factors toward good
and bad prognosis, predictive models based on multivariable
analysis of multiple prognostic factors are much more valu-
able than isolated factors. The NPI is one such factor and was
derived from the multivariable analysis of 387 patients with
different molecular subtypes of breast cancer and was later
validated in a series of 320 independent consecutive cases
[35]. Several external studies have demonstrated its ability to
give a prognostic classification of breast carcinomas [36–38].
Although the improvements in treatment have significantly
altered the outcomes of breast cancer, and this improvement
is also reflected in the NPI prognostic group-specific sur-
vivals, the prognostic separation of breast cancers on the basis
of the NPI was still found to be valid [39]. The PREDICT tool
was derived from a much greater population and was also
independently validated in a number of reports [17, 40].
PrognosTILs is a novel multivariable prognosticator model
and calculator derived from the pooled analysis of 2148 indi-
vidual patients’ data from 9 studies on TNBCs proving the
prognostic value of stromal TILs in the adjuvant setting [24].
This distinguishes it from NPI and PREDICT which were
built on data from ER-positive and ER-negative tumors to-
gether, and theoretically could mean that it is better fitted to
predict the prognosis of TNBCs.
The significance of the NPI in TNBC was first examined
by Albergaria and coauthors in 2001 with reassuring results.
NPI results correlated well with real survival data due to the
facts that TNBCs are frequently high grade and large tumors
[41]. PREDICT, to our knowledge has not yet been evaluated
for TNBCs alone, whereas PrognosTILs is relatively recent
for larger validation on comparison studies.
In univariate Cox analysis, type of surgery, pT, pN, stage,
NPI and adjuvant therapy were found significant prognostic
variables. We also found that lower 5-year OS and DFS pre-
dictions of PognosTILs are related with more frequent tumor
specific death and recurrence (pOS = 0.015, pDFS<0.001),
while the lower 5-year OS predictions of PREDICT are as-
sociated with higher rate of tumor specific death (p = 0.02).
Concerning the NPI, we demonstrated that there are signifi-
cant differences among OS and DFS estimates of certain
prognostic groups (Fig. 1). PrognosTILs and PREDICT de-
rived estimates of survival, as scale variables could not enter
the Kaplan-Meier analysis. The direct comparison of the mul-
tivariable prognosticators was performed with ROC curve
analysis. Regarding the OS follow up data, PrognosTILs,
PREDICT and NPI, while regarding the DFS follow up data,
PrognosTILs and NPI were compared. All three predictors of
outcome reflect fair performance with areas under the ROC
curves falling between 0.7 and 0.8. The sensitivity and spec-
ificity of these predicting systems are rather similar, although
there seems to be a tendency for NPI values to better predict
outcome on the basis of the somewhat greater AUC values. In
keeping with the results of Albergaria et al., the multivariate
Cox-regression strengthened that NPI is an independent pre-
dictor of OS and DFS in TNBCs (pOS = 0.006; HR:1.66,
95%CI:1.16–2.37; pDFS<0.001; HR:1.92, 95%CI:1.46–
2.53) [41]. Considering that the ROC curve analysis yielded
similar results for the three multivariable prognosticators
studied, it can be inferred that any of these is suitable to
predict the outcome of TNBCs, and none of these is inferior
to the others.
The results also show that TNBCs are prognostically het-
erogeneous. No case was classified as of very good prognosis
on the basis of the NPI, and only 3 cases fell into the good
prognostic group. This is due to the fact that only 5 tumors
were of histologic grade 2, whereas the remaining were high
grade, and with this combination, their NPI value was imme-
diately >4.
The lack of all prognostic markers for all cases and the fact
that this was a single institution study of retrospective nature
with limited number of cases are possible limitations of this
work. A further limitation may be that values predicted by
PrognosTILs and PREDICT, due to statistical reasons, could
not be entered into the multivariate Cox-regression analysis,
and could not be compared to NPI in this setting; but this
drawback was compensated by the ROC curve analysis of
the three prognosticators. Our study has strengths, as well.
To our knowledge, this study is the first to evaluate the value
of PREDICT in TNBCs, and these multivariable prognostic
tools have never been compared in a single study. Another
advantage of the study design was the uniform evaluation of
TILs with rigorous adherence to internationally agreed
guidelines.
In conclusion, our findings reflect the diverse nature of
TNBC and highlight the difficulties of predicting the outcome
of this disease. Although the NPI seemed to give somewhat
higher AUC values in the direct comparisons with PREDICT
and PrognosTILs, none of the multivariable prognosticators is
inferior to the others according to our data.
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